ArticleBulletin of experimental biology and medicine2025
Production of Recombinant Neuraminidase NA Protein of Influenza A/H5N2 Virus and Its Application for the Detection of Virus-Specific IgG to Influenza A Viruses.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The major antigens of the influenza virus are the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). Antibodies to HA are virus-neutralizing, whereas NA-specific antibodies alleviate the severity of the infection while also conferring protective immunity. In cases of genetic drift or antigenic shift among circulating influenza strains, anti-HA antibodies may show reduced cross-neutralization efficiency. Therefore, when assessing susceptibility to influenza following infection or vaccination, it is crucial to consider immune responses directed against the second principal antigenic component, NA. NA-specific antibodies have been demonstrated to possess cross-reactive and protective properties. We obtained a recombinant NA protein of influenza A virus and used it for the detection of virus-specific IgG to influenza A viruses.
Indexed as
Identifiers
41811411What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.